Caverject Impulse Patent Expiration

Caverject Impulse is a drug owned by Pfizer Inc. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 10, 2015. Details of Caverject Impulse's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5716338 Dual-chamber type injection cartridge with bypass connection
Feb, 2015

(9 years ago)

Expired
US5501673 Injection cartridge
Apr, 2013

(11 years ago)

Expired

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Caverject Impulse is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Caverject Impulse's family patents as well as insights into ongoing legal events on those patents.

Caverject Impulse's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Caverject Impulse's generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 10, 2015 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Caverject Impulse Generic API suppliers:

Alprostadil is the generic name for the brand Caverject Impulse. 2 different companies have already filed for the generic of Caverject Impulse, with Hikma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Caverject Impulse's generic

Alternative Brands for Caverject Impulse

There are several other brand drugs using the same active ingredient (Alprostadil) as Caverject Impulse. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Mylan Speciality Lp
Muse
Pfizer
Caverject


Apart from brand drugs containing the same ingredient, some generics have also been filed for Alprostadil, Caverject Impulse's active ingredient. Check the complete list of approved generic manufacturers for Caverject Impulse





About Caverject Impulse

Caverject Impulse is a drug owned by Pfizer Inc. Caverject Impulse uses Alprostadil as an active ingredient. Caverject Impulse was launched by Pfizer in 2002.

Approval Date:

Caverject Impulse was approved by FDA for market use on 11 June, 2002.

Active Ingredient:

Caverject Impulse uses Alprostadil as the active ingredient. Check out other Drugs and Companies using Alprostadil ingredient

Dosage:

Caverject Impulse is available in injectable form for injection use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
0.01MG/VIAL INJECTABLE Prescription INJECTION
0.02MG/VIAL INJECTABLE Prescription INJECTION